作者
Minesh P Mehta, William R Shapiro, Michael J Glantz, Roy A Patchell, Michael A Weitzner, Christina A Meyers, Christopher J Schultz, Wilson H Roa, Mark Leibenhaut, Judith Ford, Walter Curran, See Phan, Jennifer A Smith, Richard A Miller, Markus F Renschler
发表日期
2002/8/15
期刊
Journal of clinical oncology
卷号
20
期号
16
页码范围
3445-3453
出版商
American Society of Clinical Oncology
简介
PURPOSE: Motexafin gadolinium is a redox mediator that selectively targets tumor cells, is detectable by magnetic resonance imaging (MRI), and enhances the effect of radiation therapy. This lead-in phase to a randomized trial served to evaluate radiologic, neurocognitive, and neurologic progression end points and to evaluate the safety and radiologic response of motexafin gadolinium administered concurrently with 30 Gy in 10-fraction whole-brain radiation therapy for the treatment of brain metastases.
PATIENTS AND METHODS: Motexafin gadolinium (5.0 mg/kg/d for 10 days) was administered before each radiation treatment in this prospective international trial. Patients were evaluated by MRI, neurologic examinations, and neurocognitive tests. Prospective criteria and centralized review procedures were established for radiologic, neurocognitive, and neurologic progression end points.
RESULTS …
引用总数
学术搜索中的文章
MP Mehta, WR Shapiro, MJ Glantz, RA Patchell… - Journal of clinical oncology, 2002